CA
NZ
UK
AU
IND
US
Park Dental Partners, Inc. (NASDAQ: PARK), a leading provider of dental support services, reported second-quarter earnings of $0.66 per share, significantly surpassing the consensus estimate of $0.34. Shares of Park Dental have surged 41.1% year-to-date, reflecting investor confidence and positive market dynamics. The announcement …
The recent revenue boost stems from securing new contracts with three top‑rated children’s hospitals, which pushes the QUELIMMUNE customer roster up to twenty distinct institutions and deepens order depth across the network. By widening the client base, the company not only spreads fixed costs …
Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company focused on innovative treatments for respiratory and vascular conditions, reported strong financial results for the second quarter of 2026. The company generated approximately $170.4 million in net product sales, marking a significant 31% increase from the previous …
MannKind Corp. (NASDAQ: MNKD) occupies a niche within the biotechnology sector, currently valued at a marketCapitalizationof $1.24 billion while generating a trailing twelve-month revenue of $393.63 million. Recent FDA clearances for the pediatric indication of its inhaled insulin product, Afrezza, and for the Furoscix …
Nortech Systems Incorporated (NASDAQ: NSYS) designs and manufactures complex electromedical and electromechanical products for medical imaging, device, industrial, aerospace and defense customers. Operating across five distinct segments, the firm leverages deep engineering expertise to meet stringent performance specifications that differentiate its offerings from commodity‑type …
Arecor has published its study on AT278 in a peer-reviewed journal, underscoring vital advancements in diabetes treatment research. This publication enhances Arecor's visibility within the healthcare sector, positioning it favorably amongStakeholdersinterested in innovative diabetes solutions. Investors are likely to view this as a positive …
The considerable drop in revenue not only impactsCash Flowbut also raises concerns about Atara's ability to maintain its operational momentum in an increasingly competitive biopharmaceutical environment.
BioCardia, Inc. (NASDAQ: BCDA), a company specializing in developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, reported a net loss of $1.6 million for the second quarter of 2026. This is a reduction from the $2.0 million loss a year earlier, indicating …
Cencora (NYSE: COR) stands as a prominent medical‑distribution firm that commands a substantial portion of the United‑States pharmaceutical supply chain. The company recently communicated a shift in the handling of inventory linked to its long‑standing Walgreens partnership, signalling a modest reallocation of product flow. …
First Tracks Biotherapeutics, Inc. (NASDAQ: TRAX) sits at a $1.6 billion market capitalisation with 35,390,679 shares outstanding and $168.0 million in cash and equivalents. The loss widened to $33.4 million for the quarter and $83.9 million for the first half of the year, whileResearch …
Please wait processing your request...